{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:20:16Z","timestamp":1780392016634,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03388-5","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:27:19Z","timestamp":1773700039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levofloxacin Inhalation Solution: Superior Efficacy and Minimized Hepatotoxicity Against Chronic Pseudomonas Aeruginosa-Induced Pulmonary Infection"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-2268","authenticated-orcid":false,"given":"Langui","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0726-5358","authenticated-orcid":false,"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8349-4527","authenticated-orcid":false,"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1183-6334","authenticated-orcid":false,"given":"Mingmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3602-8816","authenticated-orcid":false,"given":"Jingna","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5096-6262","authenticated-orcid":false,"given":"Yuqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1629-9176","authenticated-orcid":false,"given":"Xiao","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-961X","authenticated-orcid":false,"given":"Shihao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4702-7654","authenticated-orcid":false,"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-0201","authenticated-orcid":false,"given":"Chuanbin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-3537","authenticated-orcid":false,"given":"Xuejuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"3388_CR1","doi-asserted-by":"publisher","first-page":"115472","DOI":"10.1016\/j.addr.2024.115472","volume":"215","author":"MO Shleeva","year":"2024","unstructured":"Shleeva MO, Demina GR, Savitsky AP. A systematic overview of strategies for photosensitizer and light delivery in antibacterial photodynamic therapy for lung infections. Adv Drug Deliv Rev. 2024;215:115472.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10474","key":"3388_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","volume":"405","author":"N Macesic","year":"2025","unstructured":"Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet. 2025;405(10474):257\u201372.","journal-title":"Lancet"},{"issue":"11","key":"3388_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41579-025-01193-8","volume":"23","author":"M Letizia","year":"2025","unstructured":"Letizia M, Diggle SP, Whiteley M. Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility. Nat Rev Microbiol. 2025;23(11):701\u201317.","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"3388_CR4","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.tim.2025.05.004","volume":"33","author":"R La Rosa","year":"2025","unstructured":"La Rosa R, Molin S, Johansen HK. Pseudomonas aeruginosa: persistence beyond antibiotic resistance. Trends Microbiol. 2025;33(10):1076\u201384.","journal-title":"Trends Microbiol"},{"issue":"2","key":"3388_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","volume":"15","author":"JB Lyczak","year":"2002","unstructured":"Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194\u2013222.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"3388_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/1040841X.2024.2429599","volume":"51","author":"J Yang","year":"2025","unstructured":"Yang J, Xu JF, Liang S. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and emerging treatment. Crit Rev Microbiol. 2025;51(5):841\u201359.","journal-title":"Crit Rev Microbiol"},{"key":"3388_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13040913","author":"M Hu","year":"2025","unstructured":"Hu M, Chua SL. Antibiotic-resistant Pseudomonas aeruginosa: current challenges and emerging alternative therapies. Microorganisms. 2025. https:\/\/doi.org\/10.3390\/microorganisms13040913.","journal-title":"Microorganisms"},{"key":"3388_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14020178","author":"P Vidal-Cort\u00e9s","year":"2025","unstructured":"Vidal-Cort\u00e9s P, Campos-Fern\u00e1ndez S, Cuenca-Fito E, et al. Difficult-to-treat Pseudomonas aeruginosa infections in critically ill patients: a comprehensive review and treatment proposal. Antibiotics. 2025. https:\/\/doi.org\/10.3390\/antibiotics14020178.","journal-title":"Antibiotics"},{"key":"3388_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050427","author":"J Singh","year":"2025","unstructured":"Singh J, Solomon M, Iredell J, et al. Overcoming Pseudomonas aeruginosa in chronic suppurative lung disease: prevalence, treatment challenges, and the promise of bacteriophage therapy. Antibiotics. 2025. https:\/\/doi.org\/10.3390\/antibiotics14050427.","journal-title":"Antibiotics"},{"key":"3388_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13110975","author":"B Schwartz","year":"2024","unstructured":"Schwartz B, Klamer K, Zimmerman J, et al. Multidrug resistant Pseudomonas aeruginosa in clinical settings: a review of resistance mechanisms and treatment strategies. Pathogens. 2024. https:\/\/doi.org\/10.3390\/pathogens13110975.","journal-title":"Pathogens"},{"issue":"1","key":"3388_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43556-024-00221-y","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xu H, Wang H, et al. Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances. Mol Biomed. 2024;5(1):62.","journal-title":"Mol Biomed"},{"key":"3388_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/toxics13040303","author":"Y Pei","year":"2025","unstructured":"Pei Y, Hamar P, Pei DS. Deciphering multidrug-resistant Pseudomonas aeruginosa: mechanistic insights and environmental risks. Toxics. 2025. https:\/\/doi.org\/10.3390\/toxics13040303.","journal-title":"Toxics"},{"key":"3388_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060800","author":"S Wahood","year":"2025","unstructured":"Wahood S, Alani O, Draw I, et al. Fluoroquinolones for dermatologists: a practical guide to clinical use and risk management. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18060800.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"3388_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/resp.14041","volume":"26","author":"M MacLeod","year":"2021","unstructured":"MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology. 2021;26(6):532\u201351.","journal-title":"Respirology"},{"issue":"12","key":"3388_CR15","first-page":"Cd011600","volume":"12","author":"WH van Geffen","year":"2023","unstructured":"van Geffen WH, Tan DJ, Walters JA, et al. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023;12(12):Cd011600.","journal-title":"Cochrane Database Syst Rev"},{"key":"3388_CR16","doi-asserted-by":"publisher","first-page":"115147","DOI":"10.1016\/j.addr.2023.115147","volume":"204","author":"R Diwan","year":"2024","unstructured":"Diwan R, Bhatt HN, Beaven E, et al. Emerging delivery approaches for targeted pulmonary fibrosis treatment. Adv Drug Deliv Rev. 2024;204:115147.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"3388_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2174\/0115672018265571231011093546","volume":"21","author":"KR Chaudhary","year":"2024","unstructured":"Chaudhary KR, Singh K, Singh C. Recent updates in inhalable drug delivery system against various pulmonary diseases: challenges and future perspectives. Curr Drug Deliv. 2024;21(10):1320\u201345.","journal-title":"Curr Drug Deliv"},{"key":"3388_CR18","doi-asserted-by":"publisher","first-page":"113953","DOI":"10.1016\/j.addr.2021.113953","volume":"177","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Fern\u00e1ndez A, Sancen\u00f3n F, Mart\u00ednez-M\u00e1\u00f1ez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021;177:113953.","journal-title":"Adv Drug Deliv Rev"},{"key":"3388_CR19","doi-asserted-by":"publisher","first-page":"124182","DOI":"10.1016\/j.ijpharm.2024.124182","volume":"657","author":"CT Dhege","year":"2024","unstructured":"Dhege CT, Kumar P, Choonara YE. Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS). Int J Pharm. 2024;657:124182.","journal-title":"Int J Pharm"},{"issue":"5","key":"3388_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1753465817691239","volume":"11","author":"K Hamed","year":"2017","unstructured":"Hamed K, Debonnett L. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Ther Adv Respir Dis. 2017;11(5):193\u2013209.","journal-title":"Ther Adv Respir Dis"},{"issue":"11","key":"3388_CR21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","volume":"183","author":"DE Geller","year":"2016","unstructured":"Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2016;183(11):1510\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3388_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","volume":"11","author":"BS Quon","year":"2014","unstructured":"Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11(3):425\u201334.","journal-title":"Ann Am Thorac Soc"},{"key":"3388_CR23","doi-asserted-by":"publisher","first-page":"120768","DOI":"10.1016\/j.ijpharm.2021.120768","volume":"604","author":"L Ding","year":"2021","unstructured":"Ding L, Wang J, Cai S, et al. Pulmonary biofilm-based chronic infections and inhaled treatment strategies. Int J Pharm. 2021;604:120768.","journal-title":"Int J Pharm"},{"key":"3388_CR24","doi-asserted-by":"publisher","first-page":"121507","DOI":"10.1016\/j.ijpharm.2022.121507","volume":"616","author":"L Zhang","year":"2022","unstructured":"Zhang L, Bera H, Wang H, et al. Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. Int J Pharm. 2022;616:121507.","journal-title":"Int J Pharm"},{"issue":"1","key":"3388_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","volume":"74","author":"S Anderson","year":"2022","unstructured":"Anderson S, Atkins P, B\u00e4ckman P, et al. Inhaled medicines: past, present, and future. Pharmacol Rev. 2022;74(1):48\u2013118.","journal-title":"Pharmacol Rev"},{"key":"3388_CR26","first-page":"131","volume":"8","author":"M Ibrahim","year":"2015","unstructured":"Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Medical Devices (Auckl). 2015;8:131\u20139.","journal-title":"Medical Devices (Auckl)"},{"key":"3388_CR27","doi-asserted-by":"publisher","first-page":"100966","DOI":"10.1016\/j.mtbio.2024.100966","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang B, Wang L, Yang Q, et al. Pulmonary inhalation for disease treatment: basic research and clinical translations. Mater Today Bio. 2024;25:100966.","journal-title":"Mater Today Bio"},{"issue":"2","key":"3388_CR28","doi-asserted-by":"publisher","first-page":"e14419","DOI":"10.1111\/1751-7915.14419","volume":"17","author":"J Canto Mangana","year":"2024","unstructured":"Canto Mangana J, Schilder KA, Bretones-Pedrinaci JI, et al. A perspective current and past modes of inhalation therapy. Microb Biotechnol. 2024;17(2):e14419.","journal-title":"Microb Biotechnol"},{"key":"3388_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121658","author":"S Magramane","year":"2023","unstructured":"Magramane S, Vlahovi\u0107 K, Gordon P, et al. Inhalation dosage forms: a focus on dry powder inhalers and their advancements. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16121658.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3388_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2020.02.023","volume":"75","author":"C Sorino","year":"2020","unstructured":"Sorino C, Negri S, Spanevello A, et al. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15\u20138.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"3388_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/jamp.2024.29110.jbf","volume":"37","author":"JB Fink","year":"2024","unstructured":"Fink JB, Stapleton KW. Nebulizers. J Aerosol Med Pulm Drug Deliv. 2024;37(3):140\u201356.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"3388_CR32","first-page":"Cd006458","volume":"4","author":"L Zhang","year":"2023","unstructured":"Zhang L, Mendoza-Sassi RA, Wainwright CE, et al. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database of Syst Rev. 2023;4(4):Cd006458.","journal-title":"Cochrane Database of Syst Rev"},{"key":"3388_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fbioe.2019.00406","volume":"7","author":"C Velino","year":"2019","unstructured":"Velino C, Carella F, Adamiano A, et al. Nanomedicine approaches for the pulmonary treatment of cystic fibrosis. Front Bioeng Biotechnol. 2019;7:406.","journal-title":"Front Bioeng Biotechnol"},{"key":"3388_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jconrel.2020.07.002","volume":"325","author":"H Douafer","year":"2020","unstructured":"Douafer H, Andrieu V, Brunel JM. Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases. J Control Release. 2020;325:276\u201392.","journal-title":"J Control Release"},{"issue":"3","key":"3388_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1128\/CMR.00101-15","volume":"29","author":"E Wenzler","year":"2016","unstructured":"Wenzler E, Fraidenburg DR, Scardina T, et al. Inhaled antibiotics for gram-negative respiratory infections. Clin Microbiol Reviews. 2016;29(3):581\u2013632.","journal-title":"Clin Microbiol Reviews"},{"issue":"5","key":"3388_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/jamp.2018.1508","volume":"32","author":"W Longest","year":"2029","unstructured":"Longest W, Spence B, Hindle M. Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs. J Aerosol Med Pulm Drug Deliv. 2029;32(5):317\u201339.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"6","key":"3388_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1517\/17425247.2010.485608","volume":"7","author":"LY Yeo","year":"2010","unstructured":"Yeo LY, Friend JR, McIntosh MP, et al. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opinion on Drug Delivery. 2010;7(6):663\u201379.","journal-title":"Expert Opinion on Drug Delivery"},{"key":"3388_CR38","unstructured":"Edge R, Butcher R. Vibrating mesh nebulizers for patients with respiratory conditions: clinical effectiveness, cost-effectiveness, and guidelines. CADTH rapid response reports: Summary with Critical Appraisal. Ottawa (ON), 2019 Jul 12."},{"issue":"3","key":"3388_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/jamp.2024.29116.mk","volume":"37","author":"M Knoch","year":"2024","unstructured":"Knoch M. New generation nebulizers. J Aerosol Med Pulm Drug Deliv. 2024;37(3):157\u201365.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"3388_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10020037","author":"SD McCarthy","year":"2020","unstructured":"McCarthy SD, Gonz\u00e1lez HE, Higgins BD. Future trends in nebulized therapies for pulmonary disease. J Pers Med. 2020. https:\/\/doi.org\/10.3390\/jpm10020037.","journal-title":"J Pers Med"},{"issue":"24","key":"3388_CR41","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.scib.2023.11.004","volume":"68","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Huang J, Wang G, et al. Polymyxin B sulfate inhalable microparticles with high-lectin-affinity sugar carriers for efficient treatment of biofilm-associated pulmonary infections. Sci Bull. 2023;68(24):3225\u201339.","journal-title":"Sci Bull"},{"key":"3388_CR42","unstructured":"Drugs and Lactation Database (LactMed\u00ae). National Institute of Child Health and Human Development. Levofloxacin. 2006. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501002\/."},{"key":"3388_CR43","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jgar.2021.10.019","volume":"29","author":"M Keikha","year":"2022","unstructured":"Keikha M, Askari P, Ghazvini K, et al. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2022;29:420\u20139.","journal-title":"J Glob Antimicrob Resist"},{"key":"3388_CR44","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products \u2014 Chemistry, Manufacturing, and Controls Documentation. 2002."},{"issue":"10342","key":"3388_CR45","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227\u201342.","journal-title":"Lancet"},{"issue":"3","key":"3388_CR46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00441-016-2541-4","volume":"367","author":"ER Weibel","year":"2017","unstructured":"Weibel ER. Lung morphometry: the link between structure and function. Cell Tissue Res. 2017;367(3):413\u201326.","journal-title":"Cell Tissue Res"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03388-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:00Z","timestamp":1780390140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03388-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"141"}}